Skip to main content
Premium Trial:

Request an Annual Quote

Sequencing Start-up Genome Corp. Lands $250K in Seed Funding from Slater Fund

NEW YORK (GenomeWeb News) - Genome Corp., a sequencing start-up based in Providence, RI, has received a $250,000 seed capital investment from the Slater Technology Fund, the companies said today.
 
Genome Corp. was founded earlier this year to develop and commercialize a sequencing method it calls “massively parallel Sanger sequencing,” a single-molecule approach that is expected to "greatly accelerate the speed and significantly reduce the cost of genome sequencing," according to the firm.
 
Company co-founder and CSO, Kevin Ulmer, founded single-molecule sequencing company SEQ Ltd. in 1987. The firm was later purchased by Amersham Biosciences. Ulmer was also involved in forming Exact Sciences, and has served as a consultant at Helicos Biosciences.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.